Logo

Galapagos Inks Target-Discovery Deal with Boehringer Ingelheim

Jan 16, 2006

NEW YORK, Jan. 16 (GenomeWeb News) - Galapagos said today that its BioFocus service division will use its siRNA-based gene collection to provide Boehringer Ingelheim with novel drug targets.

 

The three-year deal could be worth more than €2 million ($2.4 million), Galapagos said.

 

Terms of the collaboration call for BioFocus to expand its SilenceSelect siRNA-based gene collection with an additional gene set, develop a dedicated cellular assay in the field of autoimmune disease, and use this assay to run a target-discovery screen, the company said.

 

Galapagos will receive upfront fees, as well as research and development funding, and stands to receive milestone fees when certain drug-discovery criteria are met.

 

Additional terms were not provided.

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.